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Norcantharidin is the demethylated form of Cantharidin, which is the active ingredient of the blister
beetle, Mylabris, a long used Chinese traditional medicine. Though not well publicised outside China,
Norcantharidin is known to possess significant anti-hepatoma activity, and is relatively free from side
effects. In the present study, glucose oxidation in tumour and liver tissue slices harvested from hepatoma-
bearing animals was quantified by measuring the radioactivity of 14C-labelled CO released from 14C-
glucose in oxygen-enriched incubation medium. Results were expressed asa tumour/liver ratio. For
comparison, treatments with Norcantharidin, Adriamycin and with hepatic artery ligation were studied.
The mean tumour/liver ratio was 4.2+2.2 in untreated controls, but dropped significantly to 2.3+0.5
(p<0.05) with intra-arterial Norcantharidin (0.5 mg/kg) and to 2.3+0.7 (p<0.05) with intra-arterial
Adriamycin (2.4 mg/kg), and to 2.2+0.7 (p<0.05) with hepatic artery ligation. However, with intravenous
Adriamycin at 2.4 mg/kg, the mean tumour/liver ratio was reduced to only 3.5+2.0 and was not signifi-
cantly different from untreated controls. It is concluded that intra-arterial Norcantharidin is as effective as
intraarterial Adriamycin and hepatic artery ligation in suppressing tumour glucose oxidative metabolism.
These results imply that Norcantharidinmay have a role to play in the chemotherapy ofprimary livercancer.
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INTRODUCTION
As searches are underway for new anti-cancer
drugs, old drugs are being looked at as novel options
to be given by various routes of administration.
Although Mylabris, the dried body of the Chinese
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blister beetle, has been used as a traditional medicine
in China for more than two thousand years, recent
attention is being focused on its anti-cancer proper-
ties 1. The earliest record ofMylabris as a medicine can
be tracked back to 300-168 B.C. in China, and later in
a medical monograph, Materia Medica published .in
about A.D.77 in Europe2. The active constituent of
Mylabris has been identified as Cantharidin which
possesses not only anti-cancer activity but also
causes leukocytosis and haemorrhagic cystitis.66 PETER MACK et al.
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Figure 1 Chemical structure of Cantharidin and its derivatives.
From this compound, the derivatives of Disodium
cantharidate and Norcantharidin (Fig.l) were pro-
duced byWang and his co-workers2. These derivatives
were in fact more popular than Cantharidin itself,
since their anti-hepatoma activities were more potent
and yet cause minimal urinary irritation3. Amongst
them, Norcantharidin has been used in cancer therapy
in China since 1984. It has an acute LDs0that is 11-fold
liigher than that ofCantharidin. It also has the highest
anti-hepatoma activity among the derivatives, and, in
addition, it is free from any depressive effect on the
DNA synthesis of bone marrow cells2.
Many other derivatives of Cantharidin are
in existence and have been studied. These include
Hydrocantharidimide, Methyl cantharidimide and
Dehydronorcantharidin (Fig.l). Most investigations
on Cantharidin and its derivatives have, until recently,
been carried out within China and reported in their
own medical literature4-7. As a result for those
investigators outside the country, large gaps still exist
in their knowledge of these drugs and their efficacy.
At the present state of knowledge, human
cancer cell lines that are known to be sensitive
to Norcantharidin include HeLa, oesophageal carci-
noma (CaEs-17), hepatoma (BEL-7402 and SMMC-
7721) and epidermoid laryngocarcinoma (HEP2)
cells2. Murine tumours, such as Ehrlich ascites carci-
noma (EAC) and Hepatoma 22 cells, could be inhib-
ited by Disodium norcantharidate at a dose of 1.0
mg/kg in vivo2. Amongst some of the studies done
outside China, Yi et al. from Australia demonstrated
the anti-proliferative effect of Norcantharidin on hu-
man myeloid leukaemia cell (K562) While Shimi et al.
from Egypt showed that Dehydronorcantharidin pos-
sesses activity against EAC cells and could prolong
the survival of EAC-bearing mice9.
Despite the scanty data available, there has been
a mounting interest in the anti-hepatoma effect of this
agent, particularly in China itself mainly because
of the high prevalence of primary liver cancer.
Hepatocellular carcinoma is endemic in China, and
the prognosis of irresectable hepatoma is so poor that
any effective chemotherapeutic agent is perceived as a
welcome addition to the therapeutic armamentarium.
A multicentre clinical trial on the use of Nor-
cantharidinum on 244 patients with advanced
primary liver cancer was conducted in 1986 by Wang
et al. They reported an encouraging response rate of
58.6% with a 39% drop in serum alphafoeto-
protein levels. In that study, 37% had regression
of hepatomegaly and tumour shrinkage as confirmed
with ultrasonography or radioisotope scanning7.
The present study has been designed to compare
quantitatively, the efficacy of Norcantharidin in the
treatment of primary liver cancer with the conven-
tional therapeutic options ofAdriamycin administra-
tion (both intra-arterial and intravenous) and hepatic
artery ligation, using an animal hepatoma model. As
an indicator of tumour activity, the rate of tumour
glucose oxidative metabolism was used. It is long
known that most malignant tissues exhibit a high rate
of glycolysis
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oxidation in liver tumours is exaggerated compared to
normal liver tissueTM. Suppression of overall glucose
oxidation has been previously shown to follow the
experimental treatment of liver tumours with glucose
analogues and by inducing tumour ischaemia13. For
these reasons it is considered appropriate to choose
the suppression of tissue glucose oxidation as an mea-
sure of treatment efficacy. As Norcantharidin is al-
ready known to be more potent than Adriamycin in
the treatment of hepatoma at the same dose level, it
was decided to do a comparative in vivo study of the
two drugs at recommended clinical dosages (i.e. 0.5.
mg/kg for Norcantharidin and 2.4 mg/kg for
Adriamycin) rather than at equivalent doses.
Drugs and Radiochemicals
Norcantharidin were purchased in glass ampoules
of 10mg/2ml from Beijing Fourth Pharma-
ceutical Works, China. Adriamycin in 10mg vials was
purchased from Farmitalia Carlo Erbs Ltd, Herts,
Italy. Radioactive labelled D-[UL-14C]-glucose (304
mCi/mM) was purchased from Amersham, UK.
Anaesthesia
Intramuscular Ketamine at a dose of 7.5 mg/kg was




The Morris Hepatoma 7777 cell line was used in the
present study. The tumour was originally induced by
N-2-fluorenylphthalamic acid in inbred Buffalo rats TM.
Morris Hepatoma cells were maintained in monolayer
cell culture in Ham’s F12 nutrient medium supple-
mented with 10% calf serum, Penicillin 100 units/ml,
Streptomycin 0.1 mg/ml and Amphotericin 2.5 tg/ml
(Sigma, Chemical Co., St Louis, MO, USA). After 4
days of incubation at 37C in 95% air and 5% carbon
dioxide, the cells were harvested with 0.25% Trysin
(Cytosytems Co., Castle Hill Blue, Australia). Using
Trypan Blue (Sigma Chemicals, USA) the cell viabil-
ity count was performed with a haemocytometer.
The chemosensitivity of these hepatoma cells to
Adriamycin and Norcantharidin were initially ascer-
tained by in vitro clonogenic survival studies before
the planning of the animal experiments.
To establish a solid liver tumour model, a
suspension 1.5 106 cells/0.1 ml was injected
intra-parenchymally
5 just below the capsule into the
left lateral lobe of the rat liver via a small midline
laparotomy in the anaesthetised animal. The abdo-
men was then closed in two layers of continuous su-
ture. A waiting period of2-3 weeks was needed before
the tumour grew into an appropriate size for experi-
ments.
Operative Procedures
(1) Gastroduodenal artery cannulation
Anaesthetised tumour-bearing rats underwent
a midline laparotomy to expose the gastroduodenal
branch of the common hepatic artery. A fine
polyethylene cannula (Portex, 800/100/100/100, UK)
filled with normal saline, was inserted under an opera-
ting microscope in a retrograde direction into the vessel
and secured in position by a 6’0’ silk ligature. In one
group of turnout-bearing rats (n=9), single doses of
0.5 mg/kg of Norcantharidin in 0.3 ml saline were
infused over 5 min and the cannula was flushed with a
further infusion of 0.5 ml of normal saline. In another
group of animals (n=8), 2.4 mg/kg of intra-arterial
Adriamycin were similarly given. The patency of the
hepatic artery one hour after intra-arterial drug adminis-
tration was confirmed by the presence of pulsations
observable under the operating microscope, and all
animals were then sacrificed.
(2) Femoral vein cannulation
A groin incision was made in the anaesthetised rat,
following which the common femoral vein was ex-
posed. Under the operating microscope, a silicone
catheter (Dow Coming, Cat No. 602-105, USA) was
inserted into its lumen. A dose of Adriamycin at 2.4
mg/kg was infused intravenously through the cath-
eter. All animals were sacriWced one hour later.
Animals
Fifty-five male inbred adult Buffalo rats (NIH, USA)
weighing between 250-350 gm were used in this study.
All animals were fed a laboratory pellet diet (Wayne
Food, UK) and given tap water ad libitum.
(3) Hepatic artery ligation
A midline laparotomy was performed in the anaesthe-
tised rat. The falciform ligament and all peritoneal68 PETER MACK et al.
attachments to the liver and the hepatic branch of the
hepato-oesophageal artery were divided. The proper
hepatic artery, which is the continuation of the com-
mon hepatic artery after giving offthe gastroduodenal
artery, was identified and ligated by a 6’0’ silk suture.
In the experiment, all animals were sacrified one hour
after interruption of hepatic arterial blood flow.
Glucose Oxidation Measurement
The method of glucose oxidation measurement, deve-
loped by the main author, has been previously
described 13. Tissue samples weighing approximately
20 mg in wet weight were harvested separately, and
in turn, from the hepatoma and the adjacent normal
liver tissue. From each of these 20 mg samples, 4-5
tissue slices of approximately 0.3 mm thickness were
prepared with a sharp scalpel. All the slices of each
tissue sample were then incubated in 250 gl of Krebs-
Ringer bicarbonate buffer of pH 7.4 which has been
supplemented with 100 mg/dl of glucose and gassed
with carbogen (02;CO2=95:5). The incubation
medium was placed within centre wells suspended
inside glass scintillation counting vials (Kimble, Glass
Inc., Vineland, N.J, USA.) from air-tight rubber lined
caps. To the medium was added gCi of D-[UL-14C]
glucose (Amersham, UK). In the outer glass scintilla-
tion vial, 500 gl of 1M KOH was placed to trap the
14CO2formed. After 2 hours ofincubation in a shaking
water bath at 37C, metabolism was arrested by inject-
ing 50 gl of 1M HCI to the inner vial through the
rubber cap. Incubation was then continued overnight
at room temperature to allow the 14CO to be
completely trapped in the KOH. Then 10 ml of
scintillation fluid (ICN, Cat. No: 882480, USA.) was
added to the outer vials and the radioactivity was
measured with a Wallac 1410 liquid scintillation coun-
ter (Pharmacia,Finland).
In addition to the above, separate liver and tumour
specimens approximately 400-500 mg in wet weight
were harvested from the sacrificed animal and dried in
a hot air oven at45C for 3 weeks to obtain the wet wt/
dry wt ratio. The results oftumour oxidation of either
the tumour or normal liver tissue were then expressed
as dpm/mg dry weight.
Experimental Design
The study was conducted in two parts:
Experiment 1
In the first experiment, 14 rats were used and of these
6 were tumour-bearing animals and 8 were tumour-
free animals. A lapse of 3 weeks following tumour cell
transplantation was allowed in the tumour-bearing
animals on purpose, in order to obtain advanced tu-
rnouts of sizes up to 8-12 cm in volume for the study.
All animals, both tumour-free and tumour-bearing,
were sacrificed and tissue samples of approximately
20 mg each were obtained separately from the tumour
and from the liver tissue. These were assayed for their
capacity to oxidise 4C-glucose as described in the
preivous section. All results were expressed as dpm/mg
dry wt. A comparison was made between the glucose
oxidation of hepatoma and that of liver tissue in the
same tumour-bearing animals. A second comparison
was made in the glucose oxidation between tumour-
bearing liver and tumour-free liver in the two respec-
tive groups of animals.
Experiment 2
Forty-one tumour-bearing rats were used in this ex-
periment and all animals had small-sized hepatomas.
A lapse of 10-14 days after tumour cell inoculation in
the animals was allowed so that the tumour sizes at the
time of experiment were each approximately 1-2 cm3.
in volume. The objective ofusing small tumours in this
study design was two-fold. Firstly, the associated
operative difficulties of performing hepatic artery
ligation and gastroduodenal artery cannulation in the
presence of bulky liver tumour could be avoided.
Secondly, the design permits a comparison between
the tumour/liver ratio of glucose oxidation of small
tumours in this group against that of large advanced
tumours in the Experiment 1.
The 41 tumour-bearing animals in this experiment
were assigned to 5 groups as follows:
(1) Control group (n=9), in which no treatment was
given.
(2) Intravenous Adriamycin group (n=7), in which
Adriamycin was infused as a single dose of 2.4 mg/kg
in 0.3 ml saline over 5 minutes through the femoral
vein, followed by flushing with 0.5 ml of saline.
(3) Intra-arterial Adriamycin group (n=8), in which
Adriamycin was infused as a single dose of 2.4 mg/kg
in 0.3 ml saline over 5 minutes through the gastro-
duodenal artery followed by flushing with 0.5 ml of
saline.EFFECT OF NORCANTHARIDIN ON HEPATOMA 69
(4) Intra-arterial Norcantharidin group (n=9), in
which Norcantharidin was infused as a single dose of
0.5 mg/kg (recommended dose) in 0.3 ml saline over 5
minutes, followed by flushing with 0.5 ml of saline.
(5) Hepatic artery ligation group (n=8), in which all
animals had their proper hepatic artery ligated in the
manner described above.
All animals in the control group were sacrificed
untreated whereas those in the other four
treated groups were sacrificed one hour after institu-
tion of treatment. Tisssue specimens were separately
harvested from the hepatoma and adjacent normal
liver tissue and were assayed for their glucose oxida-
tion capacity. The results of glucose oxidation of the
hepatoma tisssue and ofthe normal liver tissue in each
animal was subsequently expressed as "tumour/liver
ratio" in that particular animal.
the tumour-bearing animals. They were not signi-
ficantly different from one another. The hepatoma
tissue in the tumour-bearing rats however showed a
glucose oxidation of 763.6+ 167 dpm/mg dry wt. and
was markedly higher than their corresponding normal
liver tissue (p<0.01) (Fig. 2). The mean tumour/liver
ratio was 4.3+1.1 in this group of advanced liver
tumours.
In the second experiment, mean tumour/liver ratio
in the untreated animals in the control group with
small hepatomas was 4.2+2.2. This result was very
close to the ratio obtained with the advanced tumours
in the first experiment. One hour after treatment with
intra-arterial Adriamycin (2.4 mg/kg), this tumour/
liver ratio was found to drop significantly to 2.3+0.7
(p<0.05). Similar significant reductions of this tu-













Figure 2 4C-glucose oxidation in hepatoma-bearing (n=6) and in tumour-free rats (n=8)
expressed as dpm/mg dry wt. Vertical lines on top of bars indicate standard deviations ofmeans.
The glucose oxidation ofhepatoma tissue was 4.3 times as high as the adjacent liver parenchyma
(p<0.01). No significant difference exists between the liver of tumour-bearing and the liver of
tumour-free rats.
All data were expressed as mean + standard devia-
tion. The Student’s t-test and the Analysis ofVariance
with Duncan’s multiple range test were used for statis-
tical evaluation for differences between groups.
Confidence limits for statistically significant differ-
ences were expressed at the 5% and 1% levels.
hour after hepatic artery ligation. However, when
Adriamycin was given intravenously in a dosage iden-
tical to that of the intra-arterial Adriamycin group
(i.e. 2.4 mg/kg), the tumour/liver ratio decreased
slightly after one hour to only 3.5+2.0 and this was not
significantly different from that of untreated controls
(Fig. 3).
RESULTS DISCUSSION
In the first experiment, the mean glucose oxidation of
liver tissue was 168.6+34 dpm/mg dry wt. in the tu-
mour-free rats and was 183.5+53 dpm/mg dry wt. in
Mylabris is potentially attractive as a chemo-
therapeutic drug because it possesses anti-cancer
properties and at the same time does not70 PETER MACK et al.
ontrol i.v.
Adriamycin Adrlamycin He }atic No
2.4mg/kg 2.4mg/kg Artery
n=9 n=7 n=8
Figure 3 Tumour/liver ratio of glucose oxidation in various treatment groups: Controls
(n=9), i.v. Adriamycin (n=7), i.a. Adriamycin (n=8), Hepatic artery ligation (n-8), and
i.a. Norcantharidin (n-9). *indicates statistical significance (p<0.05) when compared with
controls. Vertical lines on top of bars indicate standard deviations of means.
inhibit bone marrow cells. Its active constituent,
Cantharidin, has already been synthesised but the
latter compound has been found to irritate the
skin and the urinary bladder strongly. Disodium
cantharidate was subsequently prepared instead in an
effort to lower the intrinsic toxicity of Cantharidin.
Then it was realised that further reduction in toxicity
can be achieved by preparing the demethylated form,
Norcantharidin, without compromising on the
anti-tumour activity. In fact, this latest derivative
has been found to possess even more potent anti-
hepatoma effects than all other derivatives. In one
study where 285 hepatoma patients were treated
by Norcantharidin, the mean survival time was 11.1
months and the 1-year survival was 30%. This
compared favourably against a mean survival of 4.7
months and a 1-year survival of 17% in another
group of 102 cases treated with other conventional
chemotherapeutic agents including 5-fluorouracil,
hydroxy-camptothecine, thiophosphoramide, vincristine
and mitomycin2.
Not much is known about the mechanism of action
of Norcantharidin or its derivatives with respects to
their anti-cancer activity. In one study, exposure of
K562 cells to Norcantharidin resulted in blocking of
the cells in G2+M phase of the cell cycle8. In, another
study, the incorporation of thymidine and uridine
were affected showing that the DNA and RNA syn-
thesis in EAC-cells was significantly decreased by the
administration of Dehydronorcantharidin9. A recent
study of Norcantharidin on normal and malignant
haemopietic cells has provided some new insight into
the cellular and molecular actions of this compound 16.
It showed that Norcantharidin stimulated the cell cy-
cle progression of granulocyte-macrophage colony-
forming cells, stimulated DNA synthesis and
increased the frequency of mitotic cells in short-term
human bone marrow cultures. It also stimulated the
human bone marrow cultures. It also stimulated the
production of interleukin-l[3, colony stimulating
activity and tumour necrosis factor-oz. Continuous in
vitro Norcantharidin treatment however, inhibited
both DNA synthesis and granulo-cyte-macrophage
colony forming cell growth. Low doses of Norcan-
tharidin in HL-60, K-562 leukaemic and MRC5V2
fibroblast cell lines accelerated the GI-S phase transi-
tion while higher doses or prolonged incubations in-
hibited the cell cycle at the G2/M phases or during the
formation of postmitotic daughter cells. Norcan-
tharidin also impaired the neogenesis of chromatin
material and nuclear membrane during the M/G
phase transition in K-562 cells. These effects of
Norcantharidin may be due to its inhibitory effect on
protein phosphatase type 2A activity which regulates
the cell cycle and may partly explain its anti-cancer
activity.
The development of a useful anti-cancer drug out-
side the West with minimal documentation in the
English medical literature often invites reluctance on
the part of clinicians to adopt its usage. This typically
applies to drugs developed from Chinese traditional
medicine. In such situations it is not uncommon that aEFFECT OF NORCANTHARIDIN ON HEPATOMA 71
certain amount of laboratory evaluation to be re-
peated or extended in various forms before the scien-
tific community can come forward with some
concensus on its acceptablility. In the case ofNorcan-
thardin, which appears attractive in its use in the treat-
ment ofprimary liver cancer, the authors were inspired
to evaluate its efficacy quantitatively in an experimen-
tal setting. While suppression of glucose oxidative
metabolism was used in this experiment because it is a
quick and convenient parameter for short term
efficacy, further experiments showing its effect on tu-
mour burden at various time points following drug
administration will eventually be necessary to gener-
ate more enthusiasm in using the drug. Although the
scarcity of relevant literature in English might be re-
garded by some as a negative aspect in evaluating
studies ofthis nature, the same may be used to argue in
favour of the initiation of such studies.
The metabolic measurements in this study
confirmed that the Morris Hepatoma used is charac-
terised by high metabolic activity and is 4.2 times as
active as that of liver tissue in terms of glucose oxida-
tion. In addition, this ratio does not appear to differ
between early and advanced hepatomas. By compari-
son, a tumour/liver ratio of 10.5 was noted in
m’-methyl-p-dimethylaminoazobenzene induced
hepatoma in Sprague-Dawley (Hisaw) strain rats
2
and a ratio of 2.8 found in transplanted
colonic adenocarcinoma in the liver in Wistar-Furth
rats 13. It has been previously shown that a growing
malignant tumour behaves as a trap for glucose and
acts as a powerful hypoglycaemic factor imposing a
strain on the host to maintain glucose homeostasis 17.
The liver tissue of the tumour-bearing host, which is
the site for glucostatic functions, might be expected to
mainfest disturbances in glucose metabolism. How-
ever, no differences in glucose oxidation have been
observed between the liver tissue of tumour-free and
that of tumour-bearing rats in this study.
Following tumour treatment with intra-
arterial Norcantharidin, the tumour/liver ratio was
nearly halved at the end of the first hour. A similar
effect was also observed when the tumour was treated
with intra-arterial Adriamycin, indicating that both
drugs, when given by the arterial route, exhibit a
similar potency. When the same dosage ofAdriamycin
was given by the intravenous route, the depression in
tumour metabolism was significantly less. This can be
explained by the fact that the concentration of drug
delivered by the intravenous route to the turnout site is
significantly less when compared to that delivered by
the arterial route TM. In one study, when the hepatic
venous drug concentrations were compared between
administration by the intra-venous and the intra-arte-
rial routes, up to fivefold higher concentration
is found when given by the hepatic artery route9.
The results ofthe present study concurs with current
clinical recommendations that chemotherapy for pri-
mary liver cancer, if indicated, should preferably be
administered by the arterial route2. The results of
intravenous Adriamycin, even though it does not con-
tribute to the comparative assessment ofthe efficacy of
intra-arterial Norcantharidin, has nonetheless been
included in this study mainly because, it remains a
treatment modality that is commonly used clinically
for irresectable hepatoma. The message must be rein-
forced to the clinical oncologist that the intravenous
route should, whenever feasible, be discarded in fa-
vour ofthe intra-arterial route in the administration of
chemotherapy for primary liver cancer.
It is known that the blood flow to liver tumours are
predominantly supplied by the arterial route 2,2 and it
has been shown that ligation of hepatic artery could
inhibit liver tumour growth3’24’25, at least in the initial
stages before collaterals developed6. It is presumed
that the inhibition in tumour growth by ischae mia is
mediated through suppression oftumour metabolism.
Since hepatic artery ligation is clinically an effective,
though temporary, method of treating irresectable
liver tumours that yields consistent results, its inclu-
sion as a study group for comparison has provided a
good yardstick on which to evaluate the efficacy of all
other forms of treatment. Hepatic artery ligation has
been shown to lower the hepatoma glucose oxidation
capacity by as much as 48% after one hour in this
study. By comparison, only a 25% reduction in glucose
oxidation was achievable after one hour following
hepatic artery ligation in a metastatic liver adeno-
carcinoma model in a similar previous study1.
In conclusion, Norcantharidin is attracting interest
from clinicians because of its anti-hepatoma proper-
ties. When given by the intra-arterial route, it is as
effective as intra-arterial Adriamycin andhepatic artery
ligation in the suppression of tumour oxidative
glucose metabolism in a hepatocellular carcino-
mamodel in the rat. As this drug has minimal side effects
and does not cause bone marrow suppression, it has an
edge over Adriamycin and may potentially establish
a place in the chemotherapy of primary liver cancer in
future.72 PETER MACK et al.
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